Role of Anastrozole in Adjuvant Therapy for Postmenopausal Patients

Seminars in Oncology

Volumn 30, Issue 5 SUPPL. 16, 2003, Pages 21-29

  Buzdar, Aman U ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER INVASION; CHEMOPROPHYLAXIS; CLINICAL PHARMACOLOGY; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; EARLY CANCER; HUMAN; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0242637294     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2003.08.004     Document Type: Conference Paper

References (31)

1. Early Breast Cancer Trialists' Collaborative Group: Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 351:1451-1467, 1998
2. Brodie AMH, Njar VCO: Aromatase inhibitors and breast cancer. Semin Oncol 23:10-20, 1996 (suppl 2)
3. Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19:881-894, 2001
4. Dixon JM: Exemestane: A potent irreversible aromatase inactivator and a promising advance in breast cancer treatment. Expert Rev Anticancer Ther 2:267-275, 2002
5. Wells SA Jr, Santen RT, Lipton A, et al: Medical adrenalectomy with aminoglutethimide clinical studies in postmenopausal patients with metastatic breast carcinoma. Ann Surg 187:475-484, 1978
6. Anonymous: Formestane for advanced breast cancer in postmenopausal women. Drug Ther Bull 31:85-87, 1993
7. Buzdar AU, Jonat W, Howell A, et al: Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: Results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83:1142-1152, 1998
8. Dombernowsky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998
9. Bonneterre J, Thurlimann B, Robertson JFR, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women-Results of the TARGET (Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability) study. J Clin Oncol 18:3748-3757, 2000
10. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women-Results of a North American multicenter randomized trial. J Clin Oncol 18:3758-3776, 2000
11. Bonneterre J, Buzdar A, Nabholtz JMA, et al: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Results of two randomized trials designed for combined analysis. Cancer 92: 2247-2258, 2001
12. Yates RA, Dowsett IM, Fisher GV, et al: Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 73:543-548, 1996
13. Koberle D, Thurlimann B: Anastrozole: Pharmacological and clinical profile in postmenopausal women with breast cancer. Exp Rev Anticancer Ther 1:169-176, 2001
14. AstraZeneca Pharmaceuticals LP: Arimidex (anastrozole) tablets: Prescribing information [online]. Available at: http://www.fda.gov/cder/approval/index.htm. (accessed September 7, 2002)
15. Camp-Sorrell D: Anastrozole: An effective, second-line hormonal treatment for advanced breast cancer. Cancer Pract 5:391-393, 1997
16. Plourde PV, Dyroff M, Dowsett M, et al: Arimidex: A new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 53:175-179, 1995
17. Geisler J, King N, Dowsett M, et al: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, or in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 74: 1286-1291, 1996
18. Geisler J, Haynes B, Anker G, et al: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757, 2002
19. Geisler J, Bernsten L, Ottestad B, et al: Neoadjuvant treatment with anastrozole (Arimidex) causes profound suppression of intra-tumor estrogen levels. Proc Am Soc Clin Oncol 18:82a, 1999 (abstr 311)
20. St Peter J, Thyrum P, Yeh C, et al: Lack of effect of anastrozole, an aromatase inhibitor, on antipyrine pharmacokinetics in postmenopausal women. Clin Pharm Ther 61:172, 1997 (abstr PII-27)
21. Grimm SW, Dyroff MC: Inhibition of human metabolizing cytochromes P450 by anastrozole, a potent and selective inhibitor of aromatase. Drug Metab Dispos 25:598-602, 1997
22. Yates RA, Dowsett M, Fisher GV, et al: Arimidex (ZD1033): A selective, potent inhibitor of aromatase in postmenopausal female volunteers. Br J Cancer 73:543-548, 2001
23. ATAC Trialist's Group: Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: A sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br J Cancer 85:317-324, 2001
24. ATAC Trialist's Group: Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 359:2131-2139, 2002
25. Goss PE, Smith RE: Letrozole for the management of breast cancer. Expert Rev Anticancer Ther 2:249-260, 2002
26. Fisher B, Costantino J, Wickerham D, et al: Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388, 1998
27. Powles T, Eeles R, Ashley S, et al: Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101, 1998
28. Veronesi U, Maisonneuve P, Costa A, et al: Prevention of breast cancer with tamoxifen: Preliminary findings from the Italian randomised trial among hysterectomised women. Lancet 352:93-97, 1998
29. IBIS Investigators: First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 360:817-824, 2002
30. Cuzick J: Aromatase inhibitors in prevention-Data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial and the design of IBIS-II (the second international Breast Cancer Intervention Study). Springer Series: Recent Results in Cancer Research (in press)
31. Fisher B, Land S, Mamounas E, et al: Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience. Semin Oncol 28:400-418, 2001